Jayne S. Gurtler

953 total citations · 1 hit paper
10 papers, 743 citations indexed

About

Jayne S. Gurtler is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jayne S. Gurtler has authored 10 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 2 papers in Surgery. Recurrent topics in Jayne S. Gurtler's work include Colorectal Cancer Treatments and Studies (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Gastric Cancer Management and Outcomes (4 papers). Jayne S. Gurtler is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Gastric Cancer Management and Outcomes (4 papers). Jayne S. Gurtler collaborates with scholars based in United States, Germany and France. Jayne S. Gurtler's co-authors include Kevin M. Chin, Anja von Heydebreck, H. Grote, Petros Nikolinakos, Guy Jérusalem, Marc E. Lippman, Luc Dirix, Ralph V. Boccia, Erika Hamilton and Andres Forero‐Torres and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Jayne S. Gurtler

10 papers receiving 735 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

2017 581 citations Luc Dirix, István Takács et al. Breast Cancer Research and Treatment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jayne S. Gurtler United States	7	653	262	260	131	92	10	743
W. Jeff Edenfield United States	5	758 1.2×	278 1.1×	300 1.2×	175 1.3×	117 1.3×	5	883
Mario Liste-Hermoso United States	4	633 1.0×	181 0.7×	192 0.7×	298 2.3×	88 1.0×	7	756
Zoila A. Lopez‐Bujanda United States	11	409 0.6×	291 1.1×	197 0.8×	213 1.6×	275 3.0×	18	731
Bernadette Reyna Asuncion United States	9	425 0.7×	180 0.7×	301 1.2×	98 0.7×	147 1.6×	16	658
Coraline Bence France	10	645 1.0×	123 0.5×	443 1.7×	230 1.8×	98 1.1×	12	764
Rishab Ramapriyan United States	9	320 0.5×	158 0.6×	177 0.7×	184 1.4×	215 2.3×	18	598
Andy Karabajakian France	9	537 0.8×	138 0.5×	246 0.9×	84 0.6×	103 1.1×	19	684
Solène Perez France	5	715 1.1×	700 2.7×	107 0.4×	91 0.7×	107 1.2×	7	966
Jessica Salvini Italy	3	460 0.7×	96 0.4×	339 1.3×	90 0.7×	93 1.0×	4	551

Countries citing papers authored by Jayne S. Gurtler

Since Specialization

Citations

This map shows the geographic impact of Jayne S. Gurtler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jayne S. Gurtler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jayne S. Gurtler more than expected).

Fields of papers citing papers by Jayne S. Gurtler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jayne S. Gurtler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jayne S. Gurtler. The network helps show where Jayne S. Gurtler may publish in the future.

Co-authorship network of co-authors of Jayne S. Gurtler

This figure shows the co-authorship network connecting the top 25 collaborators of Jayne S. Gurtler. A scholar is included among the top collaborators of Jayne S. Gurtler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jayne S. Gurtler. Jayne S. Gurtler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Dirix, Luc, István Takács, Guy Jérusalem, et al.. (2017). Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Research and Treatment. 167(3). 671–686. 581 indexed citations breakdown →

Gurtler, Jayne S., et al.. (2016). P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer. Annals of Oncology. 27. ii81–ii81. 2 indexed citations

Kelly, Karen, Manish R. Patel, Jeffrey R. Infante, et al.. (2016). Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial. Cancer Research. 76(14_Supplement). CT132–CT132. 1 indexed citations

Lee, Keun-Wook, Rosine Guimbaud, Jayne S. Gurtler, et al.. (2016). P-282 JAVELIN Gastric 300: Phase 3 trial of avelumab (anti-PD-L1 antibody) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for advanced gastric or gastroesophageal junction cancer. Annals of Oncology. 27. ii82–ii82. 3 indexed citations

Moehler, Markus, Julien Taı̈eb, Jayne S. Gurtler, et al.. (2016). Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.. Journal of Clinical Oncology. 34(15_suppl). TPS4134–TPS4134. 10 indexed citations

Bang, Yung‐Jue, Lucjan Wyrwicz, Young Iee Park, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.. Journal of Clinical Oncology. 34(15_suppl). TPS4135–TPS4135. 7 indexed citations

Kelly, Karen, Manish R. Patel, Jeffrey R. Infante, et al.. (2015). Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.. Journal of Clinical Oncology. 33(15_suppl). 3044–3044. 28 indexed citations

Gulley, James L., David R. Spigel, Karen Kelly, et al.. (2015). Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.. Journal of Clinical Oncology. 33(15_suppl). 8034–8034. 71 indexed citations

García, Jorge A., Gary R. Hudes, Toni K. Choueiri, et al.. (2014). A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 120(11). 1647–1655. 26 indexed citations

10.

Deeken, John F., André Liem, David P. Hill, et al.. (2013). Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors. Cancer Chemotherapy and Pharmacology. 71(6). 1473–1483. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact